京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第19399号 / 医博第4050号 / 新制||医||1012(附属図書館) / 32424 / 京都大学大学院医学研究科医学専攻 / (主査)教授 長船 健二, 教授 川口 義弥, 教授 小川 誠司 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Glycaemic control in critically ill patients has been a topic of considerable attention for the past 20 years. In literature and at scientific meetings, there have been ongoing debates regarding the efficacy of glycaemic control in these patients with frequently entirely opposite opinions. These range from a strict invasive approach with target glycaemia 4-6 mmol/l to a liberal approach tolerating even values higher than 12 mmol/l. In the preview of this PhD thesis we have analysed so far published literature and describe the reasons for this inconsistency. According to the results of recent studies, the most significant efficacy of tight glycaemic control has been observed in cardiac surgical patients. If we consider the concept of tight glycaemic control as efficient strategy, there are three important questions remaining unanswered as follow. Does the specific algorithm-protocol play a key part in the concept of tight glycaemic control alongside the knowledge and skills of nursing staff in safe and efficient blood glucose control? What is the ideal timing of starting the strategy of tight glycaemic control (TGC) in cardiac surgical patient? And is there any benefit in outcome respect to mortality or morbidity? Do we have any more safe and efficient option or add-on to standard perioperative...

Cortisol is a glucocorticoid produced by the zona fasciculata (ZF) of the adrenal cortex. Traditionally, cortisol production and release was seen as being regulated strictly by adrenocorticotropic hormone (ACTH). While this is true of baseline cortisol levels and in response to acute mental stress, the picture is somewhat more complicated in other situations.Interleukin-6 (IL-6) contributes to the maintenance of cortisol levels in situations of prolonged immune or inflammatory stress. AMP activated protein kinase (AMPK) was investigated as a possible mediator of the action of IL-6 or as an independent actor in raising cortisol levels in response to hypoxemic or hypoglycemic stress.5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside (AICAR) was used to activate AMPK. Bovine ZF tissue fragments were exposed to AICAR alone and together with a known AMPK inhibitor, compound C. Protein or mRNA was then extracted from these tissue fragments. As an indicator of overall steroidogenic activity, these extracts were tested using RT-PCR and western blot assays for relative protein and mRNA levels of steroidogenic acute regulatory (StAR) protein, steroidogenic factor-1 (SF-1), and dosage sensitive sex reversal adrenal hypoplasia congenita gene on the X chromosome, gene 1 (DAX-1). Also a reporter gene assay was performed on H295R cells with a transfected StAR promoter.In bovine ZF tissue fragments, AICAR caused a significant increase of StAR protein and mRNA and SF-1 protein with a decrease of DAX-1 protein in a dose and time dependant manner. DAX-1 mRNA was shown to decrease in response to AICAR administration in a dose dependant manner. AICAR induced increases in StAR protein and SF-1 protein, and the attendant decrease in DAX-1 protein were all shown to be reduced by administration of compound C. This demonstrated that in this situation AICAR is acting through AMPK. When IL-6 was given with compound C the levels of StAR, SF-1, and DAX-1 were significantly reduced from samples treated with IL-6 alone. AICAR exposure also increased StAR promoter activity in a dose and time dependant manner. This AMPK induced increase in steroidogenic activity provides a possible mechanism for increased cortisol during hypoxia and hypoglycemia, and a possible mediator for IL-6 in the ZF.

Background: Type 1 diabetes in young children is a heavy parental burden. As part of pilot phase of the KIDSAP01 study, we conducted a baseline assessment in parents to study the association between hypoglycemia fear, parental well-being and child behavior. Methods: All parents were invited to fill in baseline questionnaires: hypoglycemia fear survey (HFS), WHO-5, Epworth Sleepiness Scale and Strength and Difficulties Questionnaire (SDQ). Results: 24 children (median age: 5-year, range 1-7 years, 63% male, mean diabetes duration: 3 ± 1.7 years) participated. 23/24 parents filled out the questionnaires. We found a higher score for the hypoglycemia fear behavior 33.9 ± 5.6 compared to hypoglycemia worry 34.6 ± 12.2. Median WHO-5 score was 16 (8 - 22) with poor well-being in two parents. Median daytime sleepiness score was high in five parents (>10). For six children a high total behavioral difficulty score (>16) was reported. Pro social behavior score was lower than normal in six children (<6). Parental well-being was negatively associated with HFS total (r = - 0.50, p <.05) and subscale scores (r = - 0.44, p <.05 for HFS-Worry and HFS-Behavior), child behavior (r = - 0.45, p = .05) and positively with child age and diabetes duration (r = 0.58, p <.01, r = 0.6, p <.01). HFS, parental well-being nor daytime sleepiness are associated with the HbA1c. Conclusion: Regular screening of parental well-being, hypoglycemia fear and child behavior should be part of routine care to target early intervention.

No description available.

Bakgrund: Diabetes är ett samlingsnamn för en grupp metabola sjukdomar med den gemensamma nämnaren att kroppen har en oförmåga att producera eller ta upp insulin Diabetes medför, bland annat, en risk för akuta glykemiska episoder relaterat till kroppens oförmåga att vidmakthålla en normal blodglukosnivå. Syfte: Att sammanställa kunskap om hur personer med insulinbehandlad diabetes upplever att medvetenheten om akuta glykemiska episoder påverkar det dagliga livet. Metod: En kvalitativ litteraturstudie baserad på elva vetenskapliga primärstudier inhämtade från databaserna PubMed respektive CINAHL. Resultat: Tre kategorier och sex underkategorier genererades; ”En förändrad vardag” med underkategorierna; ”Planera eller ge upp”, ”Ett behov av andras stöd” samt ”Ofrånkomliga utmaningar”, ”Att leva med oro” med underkategorierna; ”Varierande syn på lämplig blodglukosnivå”, ”Självkritik och skam” samt ”Rädsla för liv och hälsa” och ”Varierande strategier i vardagen” utan underkategorier. Slutsats: Personer med insulinbehandlad diabetes möter en mängd utmaningar i vardagen relaterat till medvetenhet om akuta glykemiska episoder. Utmaningarna inkluderar särskilda krav på minutiös planering och inte sällan förändringar i vardagen. Förändringar i vardagslivet kräver i de flesta fall implementering av nya strategier för att kunna hantera de utmaningar diabetessjukdomen medför. Utmaningarna är inte enbart av praktisk natur utan även av en mer psykosocial natur som leder till att många upplever att stigmatisering från omgivningen och orealistiska krav på sig själva resulterar i ohälsosam självkritik och ibland skam relaterat till de akuta glykemiska episoder de ofrånkomligen drabbas av i olika utsträckning. / Background: Diabetes is a collective name for a group of metabolic diseases with the denominator that the body experience an inability to produce, or absorb, insulin in sufficient quantities. Diabetes entails, amongst other potential problems, a non-unsubstantiated risk of acute glycemic episodes due to the body´s inadequate ability to maintain a normal blood glucose level. Aim: To compile knowledge on how persons suffering from insulin treated diabetes manage the awareness of the threat that acute glycemic episodes impose on everyday life. Method: A qualitative study based on eleven primary scientific studies that was obtained from the databases PubMed and CINAHL. Result: Three categories and six sub-categories emerged; “A change in everyday life” containing the sub-categories “plan or give up”, “A need for others” and “Unavoidable changes” “Living with worry” containing the sub-categories “Different views on blood glucose levels”, Self-criticism and shame” and “Fear for life and health” and lastly “Various strategies in day-to-day life” which was without sub-categories. Conclusion: People with insulin treated diabetes faces a variety of challenges in everyday life related to acute glycemic episodes. The variety of challenges include special requirements when it comes to planning and scheduling everyday life. Changes in everyday life often requires the implementation of new strategies to handle the challenges imposed by diabetes and it´s symptoms. Challenges which are not only practical in nature but also entails a more psychosocial aspect that can lead to feelings of stigmatization and unrealistic demands on one self. Feelings that can result in unhealthy self-criticism, and sometimes shame, related to the symptoms of inevitable acute glycemic episodes.

Problématique : l’activité physique est évitée par les patients atteints de diabète de type 1 (DbT1) malgré ses bénéfices et ce par crainte du risque d’hypoglycémie majoré par l’exercice. Le pancréas artificiel externe est une nouvelle technologie de trois composantes qui fonctionnent en boucle fermée, un système de surveillance continue du glucose (SSCG), un algorithme et une pompe à insuline. Peu d’études ont été conçues spécifiquement pour tester le pancréas artificiel pendant l’exercice. De plus, la précision des SSCG pourrait être compromise par les changements rapides du glucose au cours de l’exercice. Objectifs : 1) Tester et comparer l’efficacité des deux versions du pancréas artificiel, simple-hormone (insuline seule) et double-hormone (insuline et glucagon), pour prévenir l’hypoglycémie durant deux types d’exercice, en continu et par intervalles, chez les patients DbT1. 2) Comparer la performance de deux SSCG, Dexcom et Enlite, au repos et pendant l’exercice. Résultats : 1) Avec le système à simple-hormone comparé au double-hormone, 31,2% des participants ont eu au moins un épisode d’hypoglycémie nécessitant un traitement par glucides vs. 9% (p=0,02) et 24,4 ± 27,6 % de temps était passé en hypoglycémie (glucose plasmatique < 4 mmol/l) vs. 4,4 ± 14,3% (p=0,0001), respectivement. 2) Les moyennes de différence relative absolue par rapport au glucose plasmatique pour Dexcom vs. Enlite étaient comparables au repos 13,8 vs. 12,4% (p=0,53) et pendant l’exercice 22,5% vs. 20,4% (p=0,58). La comparaison repos vs exercice était significatif pour Dexcom (p=0,005) et Enlite (p=0,007). Conclusions : le pancréas artificiel à double-hormone engendre un moindre risque d’hypoglycémie et permet un meilleur contrôle de la glycémie que le système à simple-hormone. Les deux SSCG, Dexcom et Enlite ont une bonne performance, sont comparables, mais sont tous les deux moins précis durant l’exercice qu’au repos. / Background: Physical activity is often avoided by patients with Type 1 diabetes (T1D) despite its health benefits due to fear of its elevated hypoglycemic risk. The external artificial pancreas is a new technology that controls glucose via a closed-loop strategy of three components; a continuous glucose monitoring system (CGMS), an algorithm and an insulin pump. Studies of the artificial pancreas included physical activity sessions but were rarely designed to specifically assess its efficacy during exercise. Moreover, the precision of the CGMS can be affected by the rapidly changing blood glucose levels during exercise. Objectives: 1) To test and compare the efficacy of the two versions of the artificial pancreas, single-hormone (insulin only) and dual-hormone (insulin plus glucagon) during two types of exercise, continuous and interval, in patients with T1D. 2) To compare the performance of two CGMS, Dexcom and Enlite, at rest and during exercise. Results: 1) During single-hormone artificial pancreas in comparison to dual-hormone, 31.2% of the participants had at least one hypoglycemic episode necessitating treatment vs. 9% (p=0,02) and 24.4 ± 27.6 % of the time spent in hypoglycemia (plasma glucose < 4 mmol/l) vs. 4.4 ± 14.3% (p=0.0001), respectively. 2) The mean relative absolute differences (MARD) in reference to plasma glucose for Dexcom vs. Enlite were at rest 13.8 vs. 12.4% (p=0.53) and during exercise 22.5% vs. 20.4% (p=0.58). The comparison of mean ARD`s at rest vs. exercise were significant for Dexcom (p=0.005) and Enlite (p=0.007). Conclusions: The dual-hormone artificial pancreas was shown to be better than single-hormone at achieving hypoglycaemia-free control during exercise in adults with T1D. Dexcom and Enlite demonstrated comparable overall performances during rest and physical activity with a lower accuracy for both sensors during exercise.

O diabetes mellitus tipo 1 (DM1) está associado com condições pró-oxidantes, próinflamatórias e elevado risco cardiovascular, enquanto o exercício físico pode ser considerado um dos melhores instrumentos não farmacológicas para o tratamento do DM1. Nesse contexto, exercícios que propiciem um menor risco hipoglicêmico e diversos benefícios sobre a saúde devem ser estimulados. Um dos objetivos da tese foi verificar a influência da realização de exercícios de força (SE) antes ou depois do exercício intervalado de alta intensidade (HIIE) sobre o comportamento glicêmico durante e logo após uma sessão de esforço (estudo transversal) (manuscrito original 1). Entretanto, o principal objetivo desta tese foi comparar os efeitos do treinamento intervalado de alta intensidade (HIIT), do treinamento de força (ST) e da combinação destes (ST+HIIT), sobre marcadores sanguíneos inflamatórios, de estresse oxidativo (OS) e metabolismo glicêmico em pacientes com DM1 através de um ensaio clínico randomizado (ECR) (manuscrito original 2). Com relação ao estudo transversal (manuscrito 1), em três visitas, adultos fisicamente ativos realizaram 30 min de SE antes de 30 min de HIIE ou realizaram a ordem inversa da sessão (HIIE+SE) ou permaneceram em repouso nesse período (REST). A glicemia capilar foi mensurada a cada 15 min durante e até 60 min da recuperação. Comparando-se com os valores basais, a condição HIIE+SE reduziu a glicemia em 30, 45 e 60 min, enquanto SE+HIIE adiou esta queda glicêmica para a partir de 60 min. HIIE+SE também acarretou uma maior glicemia em 105 min quando comparado a 60 min. A quantidade ingerida de carboidratos durante as sessões, bem como a dose insulínica no mesmo dia antes e depois dos protocolos, além dos episódios noturnos de hipoglicemia, foram similares entre as três condições. Conclui-se que pacientes com DM1 propensos a desenvolver hipoglicemia associada ao exercício devem realizar SE antes do HIIE na mesma sessão. Com relação ao estudo principal (ECR) (manuscrito original 2), após 4 semanas de um período controle, pacientes fisicamente inativos com DM1 foram randomizados para realização de 10 semanas de HIIT, ST ou ST+HIIT, praticados 3x/sem. As sessões de HIIT duraram 25 min, as de ST 40 min, e as de ST+HIIT ~65 min. Os desfechos foram analisados através do modelo de equações de estimativas generalizadas (GEE), com post hoc de Bonferroni. ST, HIIT e ST+HIIT melhoraram parâmetros glicêmicos e antioxidantes, mas não os marcadores plasmáticos de inflamação e de OS. Interessantemente, as intervenções reduziram as concentrações de receptores solúveis para produtos finais da glicação avançada. Entretanto, o conteúdo intracelular das proteínas de choque térmico de 70 kDa aumentou somente depois do HIIT. Enquanto a dose diária de insulina utilizada reduziu apenas no grupo ST+HIIT, todos os protocolos induziram benefícios antropométricos, cardiorrespiratórios e funcionais. Sob uma perspectiva prática, conclui-se que um maior volume (ST+HIIT) de treinamento é necessário para o benefício adicional da redução insulínica diária. Já o HIIT, por exemplo, é diretamente aplicável para pessoas que reclamam da falta de tempo, podendo ser recomendado devido a vantagem extra com relação a proteínas anti-inflamatórios em células imunológicas. / Type 1 diabetes mellitus (DM1) is associated with prooxidant and proinflammatory conditions, besides an increased cardiovascular risk, while exercise may be considered one of the best nonpharmacological tools for DM1 treatment. In this context, exercises linked with a lower hypoglycemic risk and several health benefits should be stimulated. One of the goals of this thesis was to verify the influence of performing strength exercises (SE) before or after highintensity interval exercise (HIIE) on glycaemia during and postexercise (cross-sectional study) (original manuscript 1). However, the main objective of this thesis was to compare the effects of high-intensity interval training (HIIT), strength training (ST) or their combination (ST+HIIT), on blood inflammatory, oxidative stress (OS) and glycemic markers in DM1 patients using a randomized clinical trial (ECR) (original manuscript 2). Regarding the crosssectional study (original manuscript 1), in three visits, physically active adults performed 30 min of SE before 30 min of HIIE or performed the reverse order (HIIE+SE) or rested for 30 min (REST). Capillary glycaemia was measured each 15 min during and 60 min postexercise recovery. HIIE+SE lowered glycaemia at 30, 45 and 60 min compared with baseline concentrations, while SE+HIIE postponed this glucose decayment to 60 min and thereafter. HIIE+SE increased glycaemia at 105 min compared with 60 min. Carbohydrates ingested during exercise, insulin dosage at same day before and after protocols, and nocturnal hypoglycemia episodes were similar among the three conditions. DM1 patients prone to develop exercise-associated hypoglycemia should perform SE before HIIE in a single session. Regarding the main study (ECR) (original manuscript 2), after 4-week control period, physically inactive patients with DM1 were randomly assigned to 10-week HIIT, ST or ST+HIIT protocol, performed 3 x/week. HIIT sessions lasted 25 min, ST lasted 40 min and ST+HIIT sessions lasted ~65 min. Blood biochemical, anthropometric, strength and cardiorespiratory fitness variables were assessed. Outcomes were analyzed via generalized estimating equations (GEE), with Bonferroni post hoc analysis. ST, HIIT and ST+HIIT improved glycemic and antioxidant parameters, but not plasma inflammatory or OS markers. Noteworthy, interventions reduced soluble receptors for advanced glycation end products levels. However, intracellular heat shock protein 70 content increased only after HIIT. While daily insulin dosage decreased only in the ST+HIIT group, all training models induced anthropometric and functional benefits. From a practical clinical perspective, a higher volume (SE+HIIT) of training is required for the additional benefit of daily insulin reduction. The HIIT, for example, is directly applicable for people who claim lack of time, and it may be 13 recommended due to extra advantage concerning anti-inflammatory proteins at immunological cells.

Diabetes mellitus (DM) é uma das principais causas de doença renal crônica terminal. Na doença renal diabética (DRD) observa-se um curso bifásico no padrão glicêmico, na fase inicial o aumento da resistência insulínica induz a hiperglicemia e, com perda progressiva da taxa de filtração glomerular, há redução na depuração dos medicamentos anti-hiperglicemiantes e insulina, aumentando o risco de hipoglicemias. Portanto, diante da perda da função renal, a reavaliação da terapia hipoglicemiante e ajustes constantes nas doses de insulina são necessários, com intuito de otimizar o controle glicêmico e minimizar seus efeitos colaterais. A revisão da literatura mostra diversos pontos sem resposta, principalmente relacionados à dose, ajuste da terapia insulínica, seguimento e monitoração do controle glicêmico em portadores de DM e DRC. O objetivo deste ensaio randomizado, cruzado, controlado foi comparar o controle glicêmico do tratamento com insulina glargina à insulina NPH em portadores de DM2 e DRD estágios 3 e 4. Pacientes e métodos: Trinta e quatro pacientes foram randomizados para receber insulina glargina uma vez ao dia ou insulina NPH em três aplicações diárias. Insulina lispro foi prescrita três vezes ao dia, em aplicações pré-prandiais nos dois grupos. Após 24 semanas de terapia, os pacientes tiveram seu esquema de insulina trocado para terapia insulínica oposta. Testes laboratoriais foram realizados após 12, 24, 36 e 48 semanas de estudo. O sistema de monitorização continua de glicose (CGMS) foi instalado ao término de cada terapia. Resultados: Dos 34 pacientes incluídos, 29 completaram as 48 semanas propostas no estudo, 2 pacientes perderam seguimento por má adesão e 3 pacientes não completaram o estudo em decorrência a eventos adversos (1 óbito, 1 ingresso em hemodiálise e 1 evento cardiovascular, todos em uso de insulina NPH). Após 24 semanas de tratamento com insulina glargina houve uma redução estatisticamente significante da média da HbA1c de 8,86 ± 1,4% para 7,95 ± 1,1% (p=0,0285), esta diferença não foi observada com a insulina NPH (8,21 ± 1,29% para 8,44 ± 1,32%). Durante o uso de insulina glargina o número de eventos noturnos de hipoglicemia foi menor comparado a insulina NPH (p=0,046); além disso, hipoglicemia grave ocorreu apenas na terapêutica com NPH. Conclusão: O tratamento com insulina glargina foi associado a melhor controle glicêmico e a redução do risco de hipoglicemia noturna quando comparada à insulina NPH,em pacientes portadores de DM e DRC estágios 3 e 4 / Diabetes mellitus is the leading cause of chronic kidney disease (CKD). Kidney disease diagnosis and its progression require re-evaluation of hypoglycemic therapy and constant dosing adjustments, to optimize glycemic control and minimize its side effects. Long acting insulin analogs and its pharmacokinetics have not been studied in different stages of kidney disease, nor is there consensus defining appropriate dose adjustment in patients with type 2 diabetes (T2DM) and CKD. The aim of this randomized, cross-over, open-label controlled clinical trial is to compare the glycemic response to intensive insulin treatment with NPH insulin or insulin glargine in T2DM patients and CKD stages 3 and 4. The primary efficacy end point was change in A1C from baseline. Thirty-four patients were randomized to receive insulin glargine once a day or NPH insulin, three times a day. Insulin lispro was prescribed as prandial insulin to both groups. After six months, patients switched to the other insulin therapy group. Laboratory tests were performed at baseline at 12, 24, 36 and 48 weeks. A continuous glucose monitoring system was implemented after 24 weeks and at the end of protocol. Results: Total of 29 subjects have completed the two branches of study, 2 patients dropped out due to low compliance and other 3 patients as a result of adverse events (1 death, 1 ingress on dialysis program, 1 cardiovascular event; all of them were on NPH therapy). After 24 weeks, average of A1c decreased on glargine group compared to baseline 8,86 ± 1,4% to 7,95 ± 1,1% (p=0,0285), but this difference was not observed on NPH group. There were no differences of insulin doses between both groups. Glargine group showed a tendency of lower risk of nocturnal hypoglycemia compared to NPH group (p=0,046). Conclusion: Insulin glargine improved glycemic control by reducing HbA1c without gain weight and with reduced tendency toward nocturnal hypoglycemic events compared with NPH insulin

No description available.